NCT01406418View on ClinicalTrials.gov

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

CR6261 2 mg/kg

Administered as a single 2-hour intravenous infusion

BIOLOGICAL

CR6261 5 mg/kg

Administered as a single 2-hour intravenous infusion

BIOLOGICAL

CR6261 15 mg/kg

Administered as a single 2-hour intravenous infusion

BIOLOGICAL

CR6261 30 mg/kg

Administered as a single 2-hour intravenous infusion

BIOLOGICAL

CR6261 50 mg/kg

Administered as a single 2-hour intravenous infusion

BIOLOGICAL

Placebo

Administered as a single 2-hour intravenous infusion

Trial Locations (1)

66211

Quintiles Early Clinical Development, Overland Park

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Crucell Holland BV

INDUSTRY

NCT01406418 - Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus | Biotech Hunter | Biotech Hunter